SCHEMBL6829969

SCHEMBL6829969

Ic1ccccc1-c1ccsc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.52
CYP2B6 P20813 2/20 0.52
CYP2E1 P05181 1/20 0.52
PTPRC P08575 1/20 0.44
CDK8 P49336 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
IMPDH2 P12268 1/20 0.41
MAOB P27338 1/20 0.41
KDR P35968 1/20 0.40
TDO2 P48775 1/20 0.39
PDK2 Q15119 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
NQO2 P16083 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30165237 1.00 CYP2A6 (0.52) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL4946960 0.84 CYP2A6 (0.64) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL7058734 0.77 CYP2A6 (0.70) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL3181535 0.76 CYP2A6 (0.54) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL27870289 0.76 CYP2A6 (0.67) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL26259994 0.75 CYP2A6 (0.52) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL26259978 0.75 CYP2A6 (0.58) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL1310377 0.74 ALDH1A1 (0.54) CYP2A6CYP2B6CYP2E1PTPRCCDK8
SCHEMBL1309148 0.74 CYP2A6 (0.54) CYP2A6CYP2B6CYP2E1PTPRCCYP3A4
SCHEMBL5190739 0.74 ALDH1A1 (0.54) CYP2A6CYP2B6CYP2E1PTPRCCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115745805-A Synthetic method of phenanthrene and naphthocycloheptene compounds 南通大学 2023-03-07 CN claimed
CN-115745805-A Synthetic method of phenanthrene and naphthocycloheptene compounds 南通大学 2023-03-07 CN disclosed
CN-100357274-C Diaryl-enynes NPS ALLELIX CORP (CA) 2007-12-26 CN disclosed
EP-1226108-A4 DIARYL-ENYNES NPS ALLELIX CORP (CA) 2004-06-16 EP disclosed
US-6579987-B2 Reducing an ester containing ene-yne conjugated, silane and aryl or heteroaryl functionality to an alcohol; bromination, amination, desilanation, coupling and deprotecting NPS ALLELIX CORPORATION (CA) 2003-06-17 US disclosed
US-20030092769-A1 DIARYL-ENYNES NPS ALLELIX CORPORATION (CA) 2003-05-15 US disclosed
US-6525085-B2 Treating neurological and neuropsychiatric disorders NPS ALLELIX CORP. (CA) 2003-02-25 US disclosed
CN-1387507-A diaryl enynes NPS ALLELIX CORP (CA) 2002-12-25 CN disclosed
US-20020169197-A1 Diaryl-enynes NPS ALLELIX CORP. 2002-11-14 US disclosed
EP-1226108-A1 DIARYL-ENYNES NPS Allelix Corp. (CA) 2002-07-31 EP disclosed
US-6426364-B1 NERVOUS SYSTEM OR PSYCHOLOGICAL DISORDERS NPS ALLELIX CORP. (CA) 2002-07-30 US disclosed
WO-2001032602-A1 DIARYL-ENYNES NPS ALLELIX CORP. (CA) 2001-05-10 WO disclosed
CN-1023699-C Difluoromethyl compounds MERCK PATENT GMBH (DE) 1994-02-09 CN disclosed
CN-1039797-A difluoromethyl compound MERCK PATENT GMBH (DE) 1990-02-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169197-A1 Diaryl-enynes CBR3, CNR1, NR3C2 CYP2A6 1020/4885CYP2B6 1044/4885CYP2E1 306/4885
US-20030092769-A1 DIARYL-ENYNES CBR3, CNR1, CBR1 CYP2A6 1060/4885CYP2B6 1084/4885CYP2E1 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.